T G TRAFFIKGENE
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

T G TRAFFIKGENE Trademark

Serial Number: 98660534 • Registration: 8309839

T G TRAFFIKGENE is a trademark filed by UNIVERSIDADE DE SANTIAGO DE COMPOSTELA on July 22, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Colexio de San Xerome Praza do Obradoiro
Santiago de Compostela 15782 , ES

Entity Type: 99

Trademark Details

Filing Date

July 22, 2024

Registration Date

June 23, 2026

Published for Opposition

May 5, 2026

Goods & Services

Scientific and technological services, namely, scientific research, analysis, testing, modeling, chemical design, synthesis and characterization as well as related research and design services in the field of bioinformatics and structure-activity relationship research, particularly that driven by machine learning and related algorithms; Research relating to molecular sciences; Analysis in the field of molecular biology; Research in the field of gene editing technology; Biological analysis; Biological development services; Biological laboratory services; Biological research and analysis; Services of a chemical and biological laboratory; Genetic mapping for scientific purposes; Scientific research in the field of genetics; Biological research; Scientific research; Culturing of cells for others for scientific research purposes; Medical research; Chemical research; Scientific laboratory services; Chemistry services in the nature of research and development services in the field of peptide chemistry, organic chemistry, supramolecular chemistry and biological chemistry

Chemicals used in industry and science; Biological preparations for use in industry and science; Chemical reagents for molecular biology, other than for medical or veterinary use; Nucleic acids, other than for medical or veterinary purposes; Nucleic recombinant acids, other than for medical or veterinary purposes; Nucleic acids for scientific purposes; Nucleic acid for use in nucleic acid amplification processes, other than for medical use; Biological tissue cultures, other than for medical or veterinary purposes; Reagents for use in scientific apparatus for chemical or biological analysis; Biological preparation for use in cell cultures other than for medical or veterinary use; Biological indicators for monitoring sterilization processes other than for medical or veterinary purposes; Reagents for use in biological processing other than for medical or veterinary purposes; Biological preparations, other than for medical or veterinary purposes, namely, biological preparations for use in industry and science, namely, the agriculture and the food industry; Aldehydes; Active chemical ingredients for use in the manufacture of pharmaceuticals, transfection reagents for use in the manufacture of pharmaceuticals, in protein production, the manufacture of biologics, namely, viral vectors and vaccine production, the engineering of producer and stable cell lines for drug discovery and preclinical development, and laboratory kits for use in transfection procedures for use in the manufacture of pharmaceuticals, in protein production, the manufacture of biologics, namely, viral vectors and vaccine production, the engineering of producer and stable cell lines for drug discovery and preclinical development which are comprised of a peptide-based transfection reagent, nucleic acids, proteins, small molecules being organic compounds, or a combination of these elements for enhancing membrane permeation for the introduction of relevant biological molecules, gene material, proteins, peptides, and antibodies inside cultured cells; Salts being chemical preparations in the nature of salts for industrial, pharmaceutical and agricultural purposes

Pharmaceuticals in the nature of advanced therapeutic medicinal products, namely RNA therapies, gene and cell therapies, as well as enzyme replacement therapies, immunotherapies, and vaccines all for the treatment of oncological disorders, metabolic diseases, autoimmune diseases, infectious diseases, and other rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; medical preparations in the nature of medical preparations for gene therapy, immunotherapy, enzyme replacement and vaccinations all for the treatment of oncological disorders, metabolic diseases, autoimmune diseases, infectious diseases, and other rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; veterinary preparations for gene therapy for pets and farm animals, all for the treatment of oncological disorders, metabolic diseases, autoimmune diseases, infectious diseases, and other rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; sanitary preparations for medical purposes; Nucleic acid sequences for medical and veterinary purposes; Biological reagents for medical use; Biological reagents for veterinary use; Biological adjuvants for medical purposes; Biological preparations for the treatment of cancer; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Medicines for human purposes being advanced therapeutic medicinal products in the nature of RNA therapy preparations, namely, mRNA, siRNA, and antisense oligonucleotide therapies for the treatment of cancer, genetic disorders, infectious diseases, and immune-mediated diseases, gene therapy preparations for the treatment of inherited genetic disorders, cancer, and rare diseases, enzyme replacement therapies for the treatment of metabolic and lysosomal storage disorders, vaccines for prophylactic and therapeutic use, immunotherapies for the treatment of cancer, autoimmune diseases, and inflammatory diseases, and cell therapies for the treatment of cancer, genetic disorders, and degenerative diseases; Medicines for human purposes being RNA therapies, gene and cell therapies, as well as enzyme replacement therapies, immunotherapies, and vaccines all for the treatment of oncological disorders particularly melanoma or lung cancer, metabolic diseases particularly lysosomal storage diseases, autoimmune diseases, infectious diseases, and other rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Biological preparations for medical purposes for the treatment of rare diseases, genetic diseases, cancer or the prophylaxis of viral diseases; Pharmaceutical preparations, namely, advanced therapeutic medicinal products being pharmaceuticals for enzyme replacement therapies, immunotherapies, and vaccines for the treatment of oncological disorders particularly melanoma or lung cancer, metabolic diseases particularly lysosomal storage diseases, autoimmune diseases, infectious diseases, and other rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Nutraceutical preparations for therapeutic and medical purposes for the treatment of rare diseases, genetic diseases, cancer and the prophylaxis of viral diseases; Chemical preparations for pharmaceutical purposes, namely, for the treatment of rare diseases, genetic diseases, cancer and the prophylaxis of viral diseases; Chemical preparations for medical purposes, namely for the treatment of rare diseases, genetic diseases, cancer and the prophylaxis of viral diseases; Chemico-pharmaceutical preparations in the nature of formulations comprising at least a mixture of one or more peptide or peptide amphiphile molecules and one or more nucleic acids and proteins for the treatment of oncological disorders, metabolic diseases, autoimmune diseases, infectious diseases, and other rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Chemical reagents for medical or veterinary purposes; Chemical preparations for veterinary purposes, namely formulations comprising at least a mixture of one or more peptide or peptide amphiphile molecules and one or more nucleic acids and proteins for the treatment of oncological disorders, metabolic diseases, autoimmune diseases, infectious diseases, and other rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Nucleic acids for medical or veterinary purposes; Nucleic recombinant acids for medical or veterinary purposes

Medical services; Genetic testing for medical purposes; Medical treatment using cultured cells

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 23, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 23, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 5, 2026 NPUB
PUBLISHED FOR OPPOSITION
May 5, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 29, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 2, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 23, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 23, 2026 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 23, 2026 ERFR
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
Feb 19, 2026 RDX3
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
Feb 19, 2026 RDX1
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
Feb 19, 2026 RRDX
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 13, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 13, 2026 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jan 13, 2026 ERFR
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
Jan 6, 2026 RDX3
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
Jan 6, 2026 RDX1
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
Jan 6, 2026 RRDX
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 18, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 18, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Dec 18, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 14, 2025 GNFN
FINAL REFUSAL E-MAILED
Oct 14, 2025 GNFR
FINAL REFUSAL WRITTEN
Oct 14, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 24, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 29, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 29, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 29, 2025 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 29, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 29, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 29, 2025 CNRT
ASSIGNED TO EXAMINER
Jul 8, 2025 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 29, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 28, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 28, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 11, 2025 GNRN
NON-FINAL ACTION E-MAILED
Feb 11, 2025 GNRT
NON-FINAL ACTION WRITTEN
Feb 11, 2025 CNRT
ASSIGNED TO EXAMINER
Feb 11, 2025 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Feb 10, 2025 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 10, 2025 NWOS
NEW APPLICATION ENTERED
Jul 22, 2024 NWAP